<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01540136</url>
  </required_header>
  <id_info>
    <org_study_id>Sun Yat-sen University</org_study_id>
    <nct_id>NCT01540136</nct_id>
  </id_info>
  <brief_title>Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Randomized Phase III Non-inferiority Study of Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Guangdong Pharmaceutical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meizhou City Hospital Of Guangdong Provience</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III trial to study the effectiveness of nedaplatin versus cisplatin with IMRT
      chemoradiotherapy in treating patients with locoregionally advanced nasopharyngeal carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nasopharyngeal carcinoma (NPC) is endemic in Southern China and Southeast Asia. Several
      prospective randomized trials have demonstrated that concurrent chemoradiotherapy was
      superior to radiotherapy alone in the treatment of locoregionally advanced NPC.
      Cisplatin-based chemotherapy has been shown to have higher response rates in NPC than
      noncisplatin regimens. However, the patients' compliance was unsatisfactory because the
      obvious gastrointestinal toxicity of cisplatin. Nedaplatin is the new second generation
      platinum and it has slight gastrointestinal reaction. Our trial is in order to study the
      effectiveness of nedaplatin or cisplatin with intensity-modulated radiation therapy (IMRT)
      chemoradiotherapy in treating patients with locoregionally advanced NPC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Progress-free survival is calculated from the date of randomization to the date of the first progress at any site.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the toxic effects, both quantitatively and qualitatively, and quality of life (QoL) of these regimens in these patients.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Administration and Monitoring Patients will be evaluated in the clinic and eligibility and informed consent obtained. Patients will be monitored for clinical toxicity by standard NIH criteria. QoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTCQLQ-C30) and EORTC QLQ Head and Neck. A time period of 4 weeks will constitute the time for clinical safety monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR)</measure>
    <time_frame>after the completion of the chemoradiotherapy treatment (up to 9 weeks)</time_frame>
    <description>CR assessed by independent reviewers, according to the Modified Response Evaluation Criteria in Solid Tumors (RECIST) from the National Cancer Institute (NCI). Disease response evaluated after the completion of the chemoradiotherapy treatment. Complete response defined as the complete disappearance of the target and non-target lesion(s) identified at baseline after radiological evaluation by Magnetic Resonance Imaging (MRI) only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>2 years</time_frame>
    <description>The OS was defined as the duration from the date of random assignment to the date of death from any cause or censored at the date of the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional Relapse-Free Survival(LRRFS)</measure>
    <time_frame>2 years</time_frame>
    <description>The LRRFS is evaluated and calculated from the date of random assignment until the day of first locoregional relapse or until the date of the last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Metastasis-Free Survival (DMFS)</measure>
    <time_frame>2 years</time_frame>
    <description>The DMFS is evaluated and calculated from the date of random assignment until the day of first distant metastases or until the date of the last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-neoplasms sensitization effects of chemotherapy to radiotherapy</measure>
    <time_frame>radiotherapy in 20Gy、40Gy、70Gy</time_frame>
    <description>Tumor response will be evaluated by physical examination and nasopharyngoscopy when radiotherapy in 20Gy、40Gy、70Gy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness analysis</measure>
    <time_frame>completion of chemoradiotherapy</time_frame>
    <description>The determination of cost, including direct cost drug fees, inspection fees, expenses and nursing cost; cost-effectiveness analysis, such as cost-effectiveness ratio (ratio of the direct cost and short - and long-term curative effect) and incremental cost-effectiveness ratio (i.e., increasing costs and increase short or long-term efficacy ratio).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate effects of CCRT with biomarkers of response and predictors of long-term outcome</measure>
    <time_frame>before chemoradiotherapy and after chemoradiotherapy</time_frame>
    <description>Early identification of patients who will have more aggressive disease soon after diagnosis has been a major goal, we will investigate the correlate effects of CCRT with biomarkers of response and predictors of long-term outcome in these patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">402</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Nedaplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nedplatin combine with IMRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cisplatin combine with IMRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nedaplatin</intervention_name>
    <description>Nedaplatin 100mg/m2(3 weekly),D1,D22,D43 of RT</description>
    <arm_group_label>Nedaplatin</arm_group_label>
    <other_name>NDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 100mg/m2(3 weekly),D1,D22,D43 of RT</description>
    <arm_group_label>Cisplatin</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly histologically confirmed non-keratinizing nasopharyngeal
             carcinoma, including WHO II or III

          -  Original clinical staged as T1-4N1-3 or T3-4N0（according to the 7th AJCC edition）

          -  No evidence of distant metastasis (M0)

          -  Male and no pregnant female

          -  Age between 18-65

          -  WBC ≥ 4,000/mm3 and PLT ≥ 100,000/mm3

          -  With normal liver function test (ALT、AST ≤ 2.5×ULN)

          -  With normal renal function test (Creatinine ≤ 1.5×ULN)

          -  Satisfactory performance status: Karnofsky scale (KPS)&gt; 70

          -  Without radiotherapy or chemotherapy

          -  Patients must give signed informed consent

        Exclusion Criteria:

          -  Patients have evidence of relapse or distant metastasis

          -  The presence of uncontrolled life-threatening illness

          -  Receiving other ways of anti-cancer therapy

          -  Receiving radiotherapy or chemotherapy

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HaiQiang Mai, MD,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/</url>
    <description>cancer</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp</url>
    <description>cisplatin</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp</url>
    <description>nedaplatin</description>
  </link>
  <reference>
    <citation>Zheng J, Wang G, Yang GY, Wang D, Luo X, Chen C, Zhang Z, Li Q, Xu W, Li Z, Wang D. Induction chemotherapy with nedaplatin with 5-FU followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Jpn J Clin Oncol. 2010 May;40(5):425-31. doi: 10.1093/jjco/hyp183. Epub 2010 Jan 19.</citation>
    <PMID>20085903</PMID>
  </reference>
  <reference>
    <citation>Fuwa N, Kodaira T, Tachibana H, Nakamura T, Daimon T. Dose escalation study of nedaplatin with 5-fluorouracil in combination with alternating radiotherapy in patients with head and neck cancer. Jpn J Clin Oncol. 2007 Mar;37(3):161-7. Epub 2007 Mar 1.</citation>
    <PMID>17332057</PMID>
  </reference>
  <reference>
    <citation>Tanaka T, Yukawa K, Umesaki N. Radiation reduces carboplatin sensitivity and enhances nedaplatin sensitivity in cervical squamous cell carcinoma in vitro. Eur J Gynaecol Oncol. 2007;28(5):352-5.</citation>
    <PMID>17966212</PMID>
  </reference>
  <reference>
    <citation>Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, Li NW, Xiang YQ, Luo DH, Qiu F, Sun R, Deng MQ, Chen MY, Hua YJ, Guo X, Cao KJ, Hong MH, Qian CN, Mai HQ. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst. 2011 Dec 7;103(23):1761-70. doi: 10.1093/jnci/djr432. Epub 2011 Nov 4.</citation>
    <PMID>22056739</PMID>
  </reference>
  <reference>
    <citation>Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, Leung SF, Cheung FY, Yeo W, Yiu HH, Yu KH, Chiu KW, Chan DT, Mok T, Yuen KT, Mo F, Lai M, Kwan WH, Choi P, Johnson PJ. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002 Apr 15;20(8):2038-44.</citation>
    <PMID>11956263</PMID>
  </reference>
  <reference>
    <citation>Ma J, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, Lu TX, Mo HY. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001 Mar 1;19(5):1350-7.</citation>
    <PMID>11230478</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2012</study_first_submitted>
  <study_first_submitted_qc>February 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2012</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hai-Qiang Mai,MD,PhD</investigator_full_name>
    <investigator_title>Deputy Director of the Department of Nasopharyngeal Carcinoma</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nedaplatin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

